درباره این اپیزود
Brad Wyman’s seen a few things over his 30-year career: the potential of medical imaging, the limits of biomarker development, and the struggles and successes inherent to translational medicine. Join host Colin Miller as Brad shares stories from the front lines of clinical development.
- Why successful biomarkers don’t guarantee clinical success
- Engineers vs. scientists, and how Brad distinguishes between them
- Integrated approaches to marketing and business strategy
- The impact of AI, and where Brad would invest a hypothetical $100M (hint: it’s not AI)
انگلیسی
ایالات متحده آمریکا
رونوشت 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
جستجوی اپیزودهای گذشته
اپیزودهای قبلی Fractals: Life Science Conversations را جستجو کن.
قسمت های دیگر در این پادکست
Can AI help radiologists see what humans can’t—and speed up drug development in the process?
In this episode of SNiPs, Dr. Ben Larimer joins Bracken CEO Dr. Colin Miller to explore how artificial intelligence and machine learning are redefining what’s possible in molecular imaging. From interpretin…
With more than four decades of experience in oncology, cardiovascular imaging, ultrasound, and radioligand therapy, Dr. François Tranquart has helped shape the field of molecular imaging from both sides of the table—first as an academic physician and researcher, and later as an industry leader driv…
What does it take to lead successful drug development—whether at a global pharma giant or a small biotech start-up?
In this episode of SNiPs, Dr. David Krause joins Bracken CEO Dr. Colin Miller to reflect on three decades of experience spanning large organizations like GSK to fast-moving start-ups.…
With more than 30 years of experience spanning global pharma, emerging biotech, and the evolving field of personalized medicine, Bracken Senior Partner Dr. David Krause has helped shape the clinical and regulatory landscape across therapeutic areas—from vaccines and anti-infectives to neuropsychiat…
As a scientist, innovator, and CEO of CytoSite BioPharma, Dr. Ben Larimer has reshaped how we think about imaging immune response in cancer. His work on Granzyme B PET imaging is unlocking unprecedented insights into whether—and where—immunotherapies are working inside the body.
In this episode of …
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به The Bracken Group است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
